10
Shared Docs
10
Same-Page
10 / 10
Mentions
inue to like TEVA's positioning In generic pharma where scale and product diversity are increasingly important. TEVA remains one of our top picks in Spec Pharma. rontler Comm (FIR) - BAML reaffirming BUY after Frontier reported its first post-Verizon assets merger results. Fifes earnings miss was due to a de
Put costs —3.2% which given the long term chart below and all time high in shares outstanding looks cheap. Chart One shows hourly data of IEF (7.10y US Treasury ETF) and SPY (S&P500 ETF). Using 60 hourly data points, correlation has moved from around -80% a month ago to zero now. This means the volatility/levera
tinue to like TEVA's positioning In generic pharma where scale and product diversity are increasingly important. TWA remains one of our top picks In Spec Pharma. Frontier Comm (FTR) - BAML reaffirming BUY after Frontier reported its first post-Verizon assets merger results. FTR's earnings miss was due to a d
Put costs —12% which given the long term chart below and all time high in shares outstanding looks cheap. Chart One shows hourly data of IEF (7.10y US Treasury ETF) and SPY (S&P500 ETF). Using 60 hourly data points, correlation has moved from around -80% a month ago to zero now. This means the volatility/levera
tinue to like TEVA's positioning in generic pharma where scale and product diversity are increasingly important. TWA remains one of our top picks in Spec Pharma. Frontier Comm (FTR) - BAM reaffirming BUY after rontier reported its first post-Verizon assets merger results. FTR's ea nings miss was due to a dec
Put costs —12% which given the long term chart below and all time high in shares outstanding looks cheap. Chart One shows hourly data of IEF (7.10y US Treasury ETF) and SPY (S&P500 ETF). Using 60 hourly data points, correlation has moved from around -80% a month ago to zero now. This means the volatility/levera
inue to like TEVA's positioning in generic pharma where scale and pro=uct diversity are increasingly important. TEVA remains one of our top pick= in Spec Pharma. Frontier Comm (FTR) - BAM= reaffirming BUY after Frontier reported its first post-Verizon assets merger results. =TR's earnings miss was due to a
ut costs —3.2% which given the long term chart below and all time high in shares outstanding looks cheap. Chart One shows hourly data of IEF (7-1=y US Treasury ETF) and SPY (S&P500 ETF). Using 60 hourly data points, =orrelation has moved from around -80% a month ago to zero now. This means the volatil=ty/levera
inue to like TEVA's positioning in generic pharma where scale and pro=uct diversity are increasingly important. TEVA remains one of our top pick= in Spec Pharma. Frontier Comm (FTR) - BAM= reaffirming BUY after Frontier reported its first post-Verizon assets merger results. =TR's earnings miss was due to a
ut costs —3.2% which given the long term chart below and all time high in shares outstanding looks cheap. Chart One shows hourly data of IEF (7-1=y US Treasury ETF) and SPY (S&P500 ETF). Using 60 hourly data points, =orrelation has moved from around -80%a month ago to zero now. This means the volatil=ty/leverag
inue to like TEVA's positioning in generic pharma where scale and product diversity are increasingly important. TEVA remains one of our top picks in Spec Pharma. Frontier Comm (FIR) - BAML reaffirming BUY after Frontier reported its first post-Verizon assets merger results. FTR's earnings miss was due to a
ut costs —3.2% which given the long term chart below and all time high in shares outstanding looks cheap. Chart One shows hourly data of IEF (7-10y US Treasury ETF) and SPY (S&P500 ETF). Using 60 hourly data points, correlation has moved from around -80% a month ago to zero now. This means the volatility/lever
nue to like TEVA's positioning in generic pharma where scale and product diversity are increasingly important. TEVA remains one of our top picks in Spec Pharma. Frontier Comm (FTR) - BAML reaffirming BUY after Frontier reported its first post-Verizon assets merger results. FTR's earnings miss was due to a
ut costs —3.2% which given the long term chart below and all time high in shares outstanding looks cheap. Chart One shows hourly data of IEF (7.10y US Treasury ETF) and SPY (S&P500 ETF). Using 60 hourly data points, correlation has moved from around -80% a month ago to zero now. This means the volatility/levera
nue to like TEVA's positioning in generic pharma where scale and product diversity are increasingly important. TEVA remains one of our top picks in Spec Pharma. Frontier Comm (FTR) - BAML reaffirming BUY after Frontier reported its first post-Verizon assets merger results. FTR's earnings miss was due to a
t costs - 3.2% which given the long term chart below and all time high in shares outstanding looks cheap. Chart One shows hourly data of IEF (7-10y US Treasury ETF) and SPY (S&P500 ETF). Using 60 hourly data points, correlation has moved from around -80% a month ago to zero now. This means the volatility/levera
nue to like TEVA's positioning in generic pharma where scale and pro=uct diversity are increasingly important. TEVA remains one of our top pick= in Spec Pharma. Frontier Comm (FTR) - BAM= reaffirming BUY after Frontier reported its first post-Verizon assets merger results. =TR's earnings miss was due to a
ut costs -3.2% which given the long term chart below and all time high in shares outstanding looks cheap. Chart One shows hourly data of IEF (7-1=y US Treasury ETF) and SPY (S&P500 ETF). Using 60 hourly data points, =orrelation has moved from around -80% a month ago to zero now. This means the volatil=ty/levera
nue to like TEVA's positioning in generic pharma where scale and product diversity are increasingly important. TEVA remains one of our top picks in Spec Pharma. Frontier Comm (FTR) - BAML reaffirming BUY after Frontier reported its first post-Verizon assets merger results. FTR's earnings miss was due to a
t costs - 3.2% which given the long term chart below and all time high in shares outstanding looks cheap. Chart One shows hourly data of IEF (7-10y US Treasury ETF) and SPY (S&P500 ETF). Using 60 hourly data points, correlation has moved from around -80% a month ago to zero now. This means the volatility/levera
Entities connected to both Spec Pharma and US Treasury ETF

Marc Rich
PERSON
Richard Kahn
PERSON
Jeffrey Epstein
PERSON
Bloomberg L.P.
ORGANIZATIONTeva Pharma
ORGANIZATION
Paul Volcker
PERSONHans Mikkelsen
PERSONFrontier Communications
ORGANIZATIONChart One
ORGANIZATIONS&P500 ETF
ORGANIZATIONInvestment Grade Supply
ORGANIZATIONInvestment Grade ETF
ORGANIZATIONFrontier Comm
ORGANIZATIONAllergan
LOCATIONAmanda
PERSONAmanda Ens
PERSONPfd Return
PERSONBloomberg: Junk Debt Keeps Climbing Despite Plunging Oil Prices
ORGANIZATIONNon-Farm Payrolls
ORGANIZATIONPierce, Fenner & Smith Incorporated
ORGANIZATION